HER-2

  • AstraZeneca Pharma India Ltd said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer.
  • The company has been granted approval to import and market trastuzumab deruxtecan used in the treatment of select “HER-2 positive” breast cancer.
  • Globally, trastuzumab deruxtecan is approved in more than 40 countries, including the US, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
  • HER2 is a form of growth-promoting protein expressed on the surface of multiple tumours, including breast, gastric, lung and colorectal cancers.
  • It is one of the biomarkers expressed in breast cancer tumours.

SOURCE: THE HINDU, THE ECONOMIC TIMES, PIB

About sree nivas

Check Also

India-UAE Bilateral Relations Overview

Context: The Bilateral Investment Treaty (BIT) 2024 between India and the UAE has replaced the …

Leave a Reply

Your email address will not be published. Required fields are marked *